Institutional Ownership
X4 Pharmaceuticals Inc
CUSIP 98420X202COM NEWXFORQ1 2026
13D / 13G Filings
23
Schedule 13D/13G on record
Beneficial Filers
13
Distinct reporting persons
Largest Stake
14.8%
Max % of class reported
Institutional Holders
78
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
23 filings · latest Mar 6, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 6, 2026 | Morgan Stanley | 13G/A | 10.2% | 8.88M | SEC |
| 2 | Feb 17, 2026 | Trails Edge Capital Partners, LP | 13G/A | 5.8% | 5.23M | SEC |
| 3 | Feb 17, 2026 | Bain Capital Life Sciences Fund, L.P. | 13G/A | 7.4% | 7.05M | SEC |
| 4 | Feb 17, 2026 | Saturn V Capital Management LP | 13G | 7.4% | 6.43M | SEC |
| 5 | Feb 17, 2026 | Biotechnology Value Fund L P | 13G/A | 3.9% | 3.41M | SEC |
| 6 | Feb 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 2.8% | 2.45M | SEC |
| 7 | Feb 12, 2026 | Morgan Stanley | 13G | 9.4% | 8.20M | SEC |
| 8 | Feb 5, 2026 | Fmr LLC | 13G/A | 9.7% | 8.50M | SEC |
| 9 | Jan 15, 2026 | Empery Asset Management, LP | 13G/A | 10.0% | 9.04M | SEC |
| 10 | Nov 14, 2025 | Nantahala Capital Management, LLC | 13G | 10.0% | 2.24M | SEC |
13 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for X4 Pharmaceuticals Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Morgan Stanley | 9.47M | $39.10M |
| 2 | Empery Asset Management, LP | 8.94M | $36.94M |
| 3 | Fmr LLC | 8.10M | $33.47M |
| 4 | Bain Capital Life Sciences Investors, LLC | 7.97M | $32.91M |
| 5 | Perceptive Advisors LLC | 6.74M | $27.83M |
| 6 | Saturn V Capital Management LP | 6.46M | $26.67M |
| 7 | Deep Track Capital, LP | 6.34M | $26.18M |
| 8 | Kalehua Capital Management LLC | 3.72M | $15.38M |
| 9 | Braidwell LP | 3.27M | $13.52M |
| 10 | Rosalind Advisors, Inc. | 3.21M | $13.28M |